AGN — Algernon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- CA$2.81m
- CA$2.74m
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.91 | 8.59 | 8.05 | 6.06 | 6.78 |
Operating Profit | -1.91 | -8.59 | -8.05 | -6.06 | -6.78 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.9 | -8.54 | -7.73 | -6.05 | -6.78 |
Net Income After Taxes | -1.9 | -8.54 | -7.73 | -6.05 | -6.78 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.9 | -8.54 | -7.73 | -6.05 | -6.78 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.9 | -8.54 | -7.73 | -6.05 | -6.78 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.07 | -2.45 | -1.24 | -0.866 | -0.346 |